Evidence map›Paper›PMID 35570394›Full record

ArticleCancer science2022

Oxidized high mobility group B-1 enhances metastability of colorectal cancer via modification of mesenchymal stem/stromal cells.

Shingo Kishi, Rina Fujiwara-Tani, Kanya Honoki, Rika Sasaki, Shiori Mori, Hitoshi Ohmori, Takamitsu Sasaki, Yoshihiro Miyagawa, Isao Kawahara, Akira Kido and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. IGF2BP2-meidated mCell death & disease · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shingo KishiDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Rina Fujiwara-TaniDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Kanya HonokiDepartment of Orthopedics, Nara Medical University, Nara, Japan.
Rika SasakiDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Shiori MoriDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Yoshihiro MiyagawaDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Isao KawaharaDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.
Akira KidoDepartment of Orthopedics, Nara Medical University, Nara, Japan.
Yasuhito TanakaDepartment of Orthopedics, Nara Medical University, Nara, Japan.
Hiroki KuniyasuDepartment of Molecular Pathology, Nara Medical University, Nara, Japan.ORCID https://orcid.org/0000-0003-2298-8825
Nara Medical University Hospital · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 19K16564Ministry of Education, Culture, Sports, Science and Technology 20K11260Ministry of Education, Culture, Sports, Science and Technology 20K19349Ministry of Education, Culture, Sports, Science and Technology 20K21659Ministry of Education, Culture, Sports, Science and Technology 21K10143
6 · The paper itself

Abstract

High mobility group box-1 (HMGB1) is known to be a chemotactic factor for mesenchymal stem/stromal cells (MSCs), but the effect of post-translational modification on its function is not clear. In this study, we hypothesized that differences in the oxidation state of HMGB1 would lead to differences in the function of MSCs in cancer. In human colorectal cancer, MSCs infiltrating into the stroma were correlated with liver metastasis and serum HMGB1. In animal models, oxidized HMGB1 mobilized three-fold fewer MSCs to subcutaneous tumors compared with reduced HMGB1. Reduced HMGB1 inhibited the proliferation of mouse bone marrow MSCs (BM-MSCs) and induced differentiation into osteoblasts and vascular pericytes, whereas oxidized HMGB1 promoted proliferation and increased stemness, and no differentiation was observed. When BM-MSCs pretreated with oxidized HMGB1 were co-cultured with syngeneic cancer cells, cell proliferation and stemness of cancer cells were increased, and tumorigenesis and drug resistance were promoted. In contrast, co-culture with reduced HMGB1-pretreated BM-MSCs did not enhance stemness. In an animal orthotopic transplantation colorectal cancer model, oxidized HMGB1, but not reduced HMGB1, promoted liver metastasis with intratumoral MSC chemotaxis. Therefore, oxidized HMGB1 reprograms MSCs and promotes cancer malignancy. The oxidized HMGB1-MSC axis may be an important target for cancer therapy.

Indexed as

Colorectal NeoplasmsHMGB1 ProteinLiver NeoplasmsMesenchymal Stem CellsAnimalsBone Marrow CellsCell DifferentiationCell ProliferationHumansMiceHMGB1 ProteinHMGB1 protein, humancancer metastasiscolorectal cancerHMGB1mesenchymal stem cellstemness

Identifiers

PMID35570394
PMCPMC9357642
OpenAlexW4280564016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.